Clinical Trial Update: EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating EPOCH chemotherapy with or without IL-12, and EPOCH plus rituximab for AIDS-associated lymphoma; study status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aids-associated Lymphoma
• Aids-related Lymphoma

Drugs mentioned

• EPOCH chemotherapy (EPOCH)
• IL-12 (interleukin-12)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: AIDS Related Lymphoma, AIDS-Associated Lymphoma | Phase 2 | Status: COMPLETED